)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Annexin Pharmaceuticals
Annexin Pharmaceuticals (ANNX) investor relations material
Annexin Pharmaceuticals Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary22 Oct, 2026
Executive summary
NEXUS recruitment completed at 12 patients; safety and tolerability follow-up and clinical/regulatory milestones are planned through Q1 2027.
July rights issue raised SEK 19.9m; cash at 30 Sep was SEK 14.436m, expected to fund operations through February 2027.
Financial highlights
Q3 operating loss and net loss were both TSEK 9,488, versus TSEK 10,055 and TSEK 9,901, respectively, in Q3 2025.
9M operating loss was TSEK 31,595 and net loss TSEK 31,562, versus TSEK 26,612 and TSEK 26,378 in 9M 2025.
9M R&D costs rose to TSEK 23,286 from TSEK 18,240, mainly due to RVO/DR clinical studies and expanded patent portfolio.
9M cash flow from operations was TSEK -31,742 versus TSEK -27,444; period cash flow was TSEK -12,959 versus TSEK 20,539.
Outlook and guidance
DR 120-day follow-up data for three patients are expected in November 2026; initial 30-day results for three RVO patients treated after anti-VEGF are expected in December.
A Type C meeting request to FDA is planned in Q4 2026 or Q1 2027 to discuss phase 2b/3 study design and treatment strategy; meeting expected in early 2027.
NEXUS follow-up is expected to finish in Q1 2027, with topline data targeted by quarter-end; cash runway is forecast through February 2027.
Further financing alternatives are under evaluation; continued operations could be at risk if key financing assumptions are not met.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Annexin Pharmaceuticals
- Annexin's intravenous therapy shows unique, sustained retinal perfusion improvements in eye disease.ANNX
Investing in Life Science 2026 - NEXUS phase 2a study showed clinical progress and financing is secured through 2026.ANNXQ2 2026
- Promising clinical progress and planned financing position the company for continued development in 2026.ANNXQ1 2026
- Favorable phase 2a results and strengthened cash position support ongoing clinical progress.ANNXQ4 2025
- Novel therapy may transform RVO treatment by reducing injections and improving outcomes.ANNXLife Science Summit 2025
- Net loss reduced, cash runway extended to April 2026, and clinical focus shifted to ophthalmology.ANNXQ3 2025
- Net loss decreased and cash position improved as clinical development advances and financing is secured.ANNXQ2 2025
- Promising phase 2a results for ANXV in RVO and strengthened liquidity after rights issue.ANNXQ3 2024
- H1 2024 saw increased losses but strengthened cash position and promising RVO study progress.ANNXQ2 2024
Next Annexin Pharmaceuticals earnings date
Q4 202611 Feb, 2027
Annexin Pharmaceuticals
Next Annexin Pharmaceuticals earnings date
Q4 202611 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Annexin Pharmaceuticals AB is a Swedish biotechnology company focused on developing innovative therapies for cardiovascular and inflammatory diseases. Its lead product, ANXV, is a recombinant human protein, Annexin A5, which has the potential to treat conditions related to blood vessel damage and inflammation. The drug is currently undergoing clinical trials, particularly for Retinal Vein Occlusion (RVO), a condition that can lead to vision loss, and shows potential for broader applications, including in oncology. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Stockholm Stock Exchange.